Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
Anti-VEGF Therapy for Acute Thyroid Eye Disease (AcTED)

The primary objective is to assess the safety and tolerability of sub-tenon aflibercept in combination with either saline or hyaluronidase (HA) in patients with acute Thyroid Eye Disease (TED) as assessed by the incidence and severity of adverse events from baseline to day 45.

  • 0 views
  • 15 Mar, 2022
  • 1 location
Safety and Efficacy of ADVM-022 in Treatment-Experienced Patients With Neovascular Age-related Macular Degeneration

results in undertreatment and vision loss in patients with nAMD receiving anti-VEGF therapy in clinical practice.

  • 0 views
  • 07 Oct, 2022
  • 4 locations
A Phase II Trial of PD-L1 Therapy Combined With Anti-VEGF Therapy in Unresectable or Metastatic Melanoma

This research study is studying a combination of two drugs that change the immune system and tumor as a possible treatment for metastatic or unresectable stage III or IV cutaneous melanoma. The names of the study drugs involved in this study are: Atezolizumab Bevacizumab

liver metastasis
metastatic melanoma
metastasis
vegf
vascular endothelial growth factor
  • 0 views
  • 18 Oct, 2022
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases

Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular

  • 0 views
  • 04 Oct, 2022
  • 1 location
Episcleral Brachytherapy for the Treatment of Wet AMD (NEAMES)

responding to anti-VEGF therapy for nAMD. The trial will be open label and non-randomized. The study intervention is a one-time intervention and requires no alteration to the standard of care during the

  • 64 views
  • 26 Mar, 2022
  • 2 locations
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

, BRCA1, BRCA2, PALB2, CHEK2, BRIP1, RAD51C, BARD1, CDK12, CHEK1, FANCL, PP2R2A, RAD51B, RAD51D, or RAD54L who have had prior treatment with at least one immune checkpoint inhibitor or anti-VEGF

hysterectomy
liver metastasis
olaparib
RAD54L
BRCA2
  • 21 views
  • 09 Feb, 2022
  • 1 location
Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease (COATS-VEGF)

efficacy combined with another treatment, mainly laser photocoagulation. The true efficacy of anti-VEGF therapy as initial therapy, and then combined in Coats disease remains unknown. Currently, several

  • 2 views
  • 12 Feb, 2022
  • 4 locations
A Randomized Phase II Trial Evaluating Chemotherapy vs Chemotherapy Plus Bevacizumab and Atezolizumab in Advanced Combined Hepatocellular Carcinoma-Cholangiocarcinoma

This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy alone in treating patients with liver cancer that cannot be removed by surgery (unresectable) or has spread to other places in the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, …

  • 0 views
  • 27 Oct, 2022
  • 18 locations
A Phase II Study of Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinoma (BTC)

Background Hepatocellular carcinoma (HCC) is the fifth most common cancer in the world. Most people with advanced HCC survive an average of 6 to 9 months. Researchers are evaluating a combination of treatment drugs to delay the progression of HCC; aiming to help people with HCC live longer. Objective To …

TACE
measurable disease
pet scan
EGFR
neutrophil count
  • 0 views
  • 23 Oct, 2022
  • 1 location
Extension Study to Evaluate the Long-term Outcomes of Subjects in the CLS-AX CLS1002-101 Study

This is an open-label, non-interventional extension study of up to 12 weeks in duration in subjects completing Cohorts 2, 3, and 4 of the Parent study, CLS1002-101.

  • 0 views
  • 26 May, 2022
  • 5 locations